The Cooper Cos., Inc.

As of November 7, 2025, The Cooper Cos., Inc. is considered expensive and overvalued with a P/E ratio of 36, a PEG ratio of 1.69, and a year-to-date return of -23.07%, underperforming the S&P 500's 14.40%.

As of November 7, 2025, The Cooper Cos., Inc. is considered overvalued with a valuation grade of "expensive," reflected in its high P/E ratio of 36 and poor year-to-date performance of -23.75% compared to the S&P 500's 14.40%.

As of November 7, 2025, The Cooper Cos., Inc. is considered expensive and overvalued with a P/E ratio of 36 compared to peers like Hologic and Align Technology, and despite a recent positive return, its year-to-date performance is significantly lower than the S&P 500.

As of October 17, 2025, The Cooper Cos., Inc. is considered very expensive and overvalued with a P/E ratio of 36, a PEG ratio of 1.69, and disappointing year-to-date performance of -21.71%, significantly underperforming the S&P 500's 13.30% return.

As of October 17, 2025, The Cooper Cos., Inc. is considered overvalued with a P/E ratio of 36 and has underperformed the S&P 500, showing a year-to-date return of -21.71% compared to the index's 13.30%.

As of October 3, 2025, The Cooper Cos., Inc. is in a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearish signals, despite some mildly bullish indicators in MACD and KST, and it has significantly underperformed the S&P 500 with a year-to-date return of -23.35%.

As of October 3, 2025, The Cooper Cos., Inc. is in a mildly bearish trend, with mixed signals from technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -23.35%.

As of September 9, 2025, The Cooper Cos., Inc. is in a bearish trend with weak strength, indicated by bearish moving averages and mixed signals from MACD, KST, and OBV, while significantly underperforming the S&P 500 with a year-to-date return of -26.88%.

As of September 11, 2025, The Cooper Cos., Inc. is considered overvalued with a P/E ratio of 36 and an EV to EBITDA of 15.35, significantly underperforming the S&P 500 with a year-to-date return of -26.88% compared to the index's 12.22%.

As of June 20, 2025, the technical trend has shifted to a bearish stance, supported by bearish MACD readings, moving averages, and KST indicators, despite a bullish weekly RSI.

As of May 30, 2025, The Cooper Cos., Inc. is considered overvalued with a P/E ratio of 36, low returns on equity and capital, and a year-to-date stock decline of 24.38%, contrasting with the S&P 500's gain of 2.44%.

As of March 2022, The Cooper Cos., Inc. management team includes A. Thomas Bender (Independent Chairman), Albert White (President & CEO), Allan Rubenstein (Independent Vice Chairman), Robert Weiss, Colleen Jay, and William Kozy (all Independent Directors). They are responsible for the company's strategic direction and governance.

The Cooper Companies, Inc. is a global medical device company in the Pharmaceuticals & Biotechnology industry, with a market cap of approximately $14 billion and quarterly net sales of $1 billion. Key financial metrics include a P/E ratio of 36.00 and a return on equity of 5.00%.

As of Jun 18, The Cooper Cos., Inc. has a market capitalization of $14.02 billion, with net sales of $3.99 billion and a net profit of $414.20 million over the last four quarters.